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Abstract
Elderly  people  are  more  likely  than younger  people  to  get  flu complications  and
respond suboptimally to influenza vaccination because of the presence of comorbidities
and immunosenescence. In order to collect information about this issue, we evaluated
data obtained in 27 winters of study, from 1988–1989 to 2014–2015, in frail  elderly
institutionalized people (≥60 years) vaccinated with commercially available seasonal
trivalent  inactivated  influenza  vaccines.  The  antibody  response  was  examined
comparing hemagglutination inhibition antibody titers  in  sera  collected from 4461
volunteers before and 30 days after vaccination. Examining the results as crude mean
responses, we evidenced the ability of influenza vaccines to induce significant increases
in antibody titers against all the three vaccine antigens satisfying at least one of the
three criteria of the Committee for Medical Products for Human Use (CHMP). Higher
responses were found against A/H3N2 vaccine components and, examining different
subgroups, in volunteers receiving 45 μg vaccine as compared with 30 μg and in female
as compared with male subjects. Very elderly people (>75 years) gave better responses
than younger elderly (≤75 years) at least against A/H1N1 strain and the last licensed
potentiated vaccines  (MF59-adjuvanted and intradermal)  were  more  immunogenic
than traditional vaccines (whole, subunit, and split).
Keywords: influenza vaccination, vaccine immunogenicity, HI antibody titers, CHMP
criteria, elderly institutionalized people
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1. Introduction
Influenza virus infections can affect all age groups, and older individuals are particularly at
risk for  influenza since,  despite  having no higher attack rate than younger adults,  most
influenza-related deaths and severe complications occur in this age group. Although influenza
vaccination remains the mainstay in prevention,  nonetheless,  uncertainties regarding the
effectiveness of the influenza vaccines in elderly adults are persistent [1, 2].
The higher rate of flu complications and the reduced vaccine efficacy are generally attributed
to both concomitant comorbidities and immunosenescence, i.e., the age-related weakening of
the immune system [3, 4].
As reported by Lambert et al. [5], the measurement of vaccine efficacy against influenza illness
is a difficult task especially in older adults. Although influenza vaccine effectiveness depends
not only on vaccine-induced immune response but also on annual variations in influenza
incidence, circulating strain virulence, and the quality of the vaccine-to-circulating strain
match [6], previous studies have established that a high serum antibody level can prevent
infection at least in children and young adults [7–9], and serological studies based on the
evaluation of influenza-specific antibody titers have been widely accepted and used as a
surrogate marker for protection against influenza and vaccine efficacy.
Chronic underlying diseases, particularly cardiac and respiratory diseases, were shown to
negatively influence the immune response after influenza vaccination in old people [10].
Three previous reviews on serological responses to inactivated seasonal vaccines in elderly
people did not consider the possible role of chronic underlying illnesses, because there was
not the possibility of controlling for the presence of serious illnesses [11] or because the elderly
population was carefully selected to exclude any chronic diseases so that the results would
reflect the effect of ageing on comparison with young people [12, 13].
In comparison with community-dwelling elderly people, residents of nursing homes are
considered to be at a higher risk of serious influenza-related complications, because they are
generally older, more debilitated, and more exposed to influenza infection once the virus is
introduced because of the close environment in which they live [14]. However, evaluating
vaccine immunogenicity, results reported in the review of Goodwin et al. [12] and results
previously obtained in our laboratory [15] suggested that institutionalized elderly responded
better when compared with community-dwelling elderly.
The aim of this chapter of the book is to examine the phenomenon of the decreased immuno-
genicity and efficacy of influenza vaccines in older persons from available data. We examined
the data obtained by our research group in 27 winter seasons, from 1988–1989 to 2014–2015,
of vaccine immunogenicity in a considerable number (4461) of elderly people (≥60 years of
age), most of them with underlying medical conditions, vaccinated with commercially
available seasonal trivalent inactivated influenza vaccines. Although some of the results
obtained in the different winters were previously published, in the present report the results
we obtained are cumulatively examined for the first time.
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2. Materials and methods
2.1. Study design and vaccination
The volunteers initially enrolled in the prospective study of antibody response to influenza
vaccination, conducted over a period of 27 consecutive winters, were 4461 elderly people,
aged ≥60 years (mean age 80.5 year, range 60–106 years). Eighty-six percent of them were
living in nursing homes in Central Italy.
After providing informed consent, all the subjects received one dose of trivalent inactivated
influenza vaccine intramuscularly, in the deltoid, or intradermally. The vaccines used were
commercially available inactivated trivalent vaccines for the winters from 1988–1989 to 2014–
2015 produced by propagation of the virus in embryonated hens’ eggs. Each dose of vaccine
consisted of 10 μg (from 1988–1989 to 1991–1992) or 15 μg of hemagglutinin (HA) in a 0.5 ml
dose (for vaccines administered intramuscularly) or in a 0.1 ml dose (for vaccines administered
intradermally) for each of the three influenza strain antigens (A/H3N2, A/H1N1, and B
influenza viruses). At the time of recruitment of this study, demographic data, health status,
and history of influenza vaccination over the preceding year were obtained from each subject.
Serum samples were obtained from the same subject before and 1 month after vaccination.
Subjects were included in this study if they did not have a history of immediate hypersensi-
tivity to eggs components. Subjects suffering from specific illnesses or chronic condition were
not excluded. The study was conducted according to the Declaration of Helsinki and Good
Clinical Practices. Since vaccines were assigned by local health authorities within the annual
influenza campaign and sera were leftover sera from samples collected for clinical routine
controls, the study did not need to be registered as a formal trial.
2.2. Determination of hemagglutination-inhibiting (HI) antibody titers and measurement
results
HI antibody titers were determined using a standard microtiter method [16] with 0.5%
chicken (from 1988–1989 to 1996–1997) or turkey erythrocytes (after 1996–1997). Antigens
were prepared from the allantoic fluids of embryonated hens’ eggs inoculated 3 days earlier
with influenza virus. All sera were heat-inactivated at 56°C for 30 min and treated with po-
tassium periodate and trypsin (from 1988 to 1994) or with receptor-destroying enzyme
(RDE) of Vibrio cholerae (after 1994) to remove nonspecific inhibitors. The first dilution for an-
tibody titration was 1:10. Pre- and postvaccination sera from each of the vaccines were fro-
zen at −30°C until used and tested simultaneously for HI antibody titers using the same
antigens as those in the vaccine. To eliminate any subjective bias, HI titers determinations
were carried on in a blind fashion, i.e., with the tester unaware of which treatment the donor
had received.
2.3. Criteria used for evaluating vaccines immunogenicity
HI antibody titers obtained by following the procedure indicated in the previous section
were reported as protection rate (percentage of volunteers showing HI titers ≥40, considered
to be associated with protection from influenza infection) [9], geometric mean titers (GMT;
Antibody Responses after Influenza Vaccination in Elderly People: Useful Information from a 27-Year Study...
http://dx.doi.org/10.5772/104559
217
any HI antibody titer <10 was considered equal to 5 for GMT calculation), ratio of postvacci-
nation to prevaccination GMT values (GMTR), and seroconversion rate (percentage of sub-
jects with a fourfold or greater increase in titer and with a postvaccination titer at least equal
to 40 in seronegative volunteers). The antibody titers measured 1 month after vaccination
were also evaluated according to the criteria of the Committee for Medicinal Products for
Human Use (CHMP) for approval of influenza vaccines, which require that for individuals
aged ≥60 years at least one of the following values must be met: seroprotection rate ≥60%,
GMTR ≥2, or seroconversion rate ≥30% [17].
2.4. Statistical analyses
Statistical analyses and subanalyses considered in this work were applied to populations
with a relatively large number of people, as a consequence both GMT and rate statistics
were well approximated by a log normal and normal distributions, respectively. Moreover,
since rates values were not close to 0 or 100%, thus significant differences between mean val-
ues of the groups were analyzed by Student’s t-test. Both estimated mean values with their
corresponding 95% confidence intervals (CI) the p-value of the t-statistic have been reported
in the paper. In particular, p-values <0.01 were considered highly statistically significant,
whereas p-values <0.05 were regarded as marginally statistically significant. Values of post-
vaccination GMT observed against different antigens and in different years were examined
as such and also corrected for prevaccination status according to Beyer et al. [18] in order to
verify that significant differences in the postvaccination status were independent on the pre-
vaccination HI titers. Vaccine response was evaluated also according to the dosage of vac-
cine antigens (30 and 45 μg), gender, and age (≤75 and >75). For each antigen, significant
differences between subpopulations means were evaluated and the corresponding statistical
significance was indicated.
A multiple comparison test between groups of vaccine type and between antigens was
executed by using one-way analysis of variance (ANOVA). Paired comparison values were
presented only when one-way ANOVA comparison identified potentially significant differ-
ences. All statistical analyses were carried out using MATLAB® of MathWorks Inc. release
2014b.
3. Results
3.1. Study population and demographic characteristics
Table 1 reports the baseline characteristics of the 4461 elderly volunteers, aged ≥60 years
(range 60–106) vaccinated with commercially available seasonal trivalent inactivated influ-
enza vaccines for each year of the 27 consecutive winters (from 1988–1989 to 2014–2015)
studied. The number of volunteers examined each year varied from 64 to 372. The mean age
was lower in the first years studied (from 1988–1989 to 1998–1999) when a mixed population
of community-dwelling and institutionalized elderly was examined (60–80 years) than in the
other seasons when volunteers were totally recruited from nursing homes (82–86 years). The
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majority of elderly subjects has been previously vaccinated (61–100%). Although not report-
ed in Table 1, percentage of volunteers, ≥80%, presented underlying diseases or risk factors
for influenza and as a consequence used chronic drugs. The most frequent chronic diseases
were cardiovascular, respiratory diseases, and diabetes. The most frequent drugs used were
antihypertensive/inotropic drugs and benzodiazepines.
Type of seasonal vaccine useda
Season No. of
subjects
Mean age
(range) 
Living
situationb
Vaccination
status prior to
studyc
Whole Sub-u Split MF59 ID Vaccine
dosage
1988–1989  282 73 (61–93) M na 232 50 – – – 30 μg
1989–1990  82 69 (60–83) M 88% – 59 23 – – 30 μg
1990–1991  372 66 (60–87) M 69% 159 213 – – – 30 μg
1991–1992  124 69 (60–93) M 61% 108 – 16 – – 30 μg
1992–1993  270 nd (>60) M 96% 245 8 17 – – 45 μg
1993–1994  298 76 (60–99) M na 51 – 247 – – 45 μg
1994–1995  235 78 (60–100) M 90% 32 – 203 – – 45 μg
1995–1996  213 77 (60–100) M 90% – 213 – – – 45 μg
1996–1997  173 80 (60–99) M 96% – 173 – – – 45 μg
1997–1998  176 na (>60) M 85% 36 140 – – – 45 μg
1998–1999  116 74 (60–102) M 94% – 110 6 – – 45 μg
1999–2000  139 83 (60–103) I 96% – 46 78 15 – 45 μg
2000–2001  128 83 (60–103) I 100% – 82 46 – – 45 μg
2001–2002  96 82 (60–104) I 98% – – 96 – – 45 μg
2002–2003  107 82 (60–105) I 100% – – 107 – – 45 μg
2003–2004  125 83 (60–101) I 100% – – 33 92 – 45 μg
2004–2005  158 82 (60–99) I 98% – – 36 122 – 45 μg
2005–2006  105 83 (60–99) I 100% – – 40 65 – 45 μg
2006–2007  88 83 (60–98) I 98% – – 21 67 – 45 μg
2007–2008  66 84 (61–102) I 100% – – – 66 – 45 μg
2008–2009  114 83 (60–103) I 98% – – – 114 – 45 μg
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Type of seasonal vaccine useda
Season No. of
subjects
Mean age
(range) 
Living
situationb
Vaccination
status prior to
studyc
Whole Sub-u Split MF59 ID Vaccine
dosage
2009–2010  64 83 (65–98) I 100% – – – 64 – 45 μg
2010–2011  112 85 (64–101) I 100% – – – 112 – 45 μg
2011–2012  151 84 (65–102) I 98% – – – 103 48 45 μg
2012–2013  252 85 (60–103) I 100% – – 26 137 89 45 μg
2013–2014  204 86 (60–106) I 100% – – – 183 21 45 μg
2014–2015  211 84 (60–104) I 100% – – 1 203 7 45 μg
Total 4461 85 (60–106) 863 1094 996 1343 165
aWhole: whole-virus vaccine; Sub-u: sub-unit vaccine; Split: split-virus vaccine; MF59: subunit MF59-adjuvanted
vaccine; ID: Intradermal subunit vaccine.
bI: Institutionalized elderly; M: mixed, both institutionalized and community living elderly.
cPercent of elderly having received influenza vaccination in the previous year.
na: not available
Table 1. Characteristics of studied population and type of influenza vaccines in the 27 winter seasons studied (from
1988/1989 to 2014/2015).
3.2. Vaccines
As reported in Table 1, different formulations such as whole, split (composed by viruses dis-
rupted, by a detergent, and containing the internal and external component of the virus),
and subunit (composed of just the purified surface glycoproteins of the virus, i.e., hemagglu-
tinin (HA) and neuraminidase) of trivalent inactivated vaccines were used in the different
years or in the same year. In the first four studied years (from 1988–1989 to 1991–1992), the
HA concentration for each strain was lower (10 μg for each antigen) as compared with the
concentration (15 μg for each antigen) of the vaccines used in all the years after the winter
season 1991–1992. Whole and subunit formulations were administered respectively to 863
and 1094 volunteers in the first 13 years of the study (from 1988–1989 to 2001–2002). Nine
hundred ninety-six elderly people were vaccinated with split vaccine in many years studied
and, starting from the 1999–2000 season, 1343 volunteers received a subunit vaccine potenti-
ated with MF59 adjuvant. In the last period of the study, a limited number of elderly people
was vaccinated with vaccine administered intradermally (165 volunteers from 2011–2012 to
2014–2015). The percentages of previously influenza-vaccinated people were high and
ranged from 88 to 100%, not considering 3 years (1990–1991, 69%; 1991–1992, 61%, and 1993–
1994, data not available).
The antigenic composition of the vaccines used is reported in Figure 1 and each year was
formulated according to the recommendations of both “Ministero della Salute (Italy)” and
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WHO (Northern Hemisphere) for the corresponding studied winter. During the 27-year period
covered by our study (1988–2014), the WHO recommended 15 A/H3N2, 7 A/H1N1, and 12 B
new influenza strains for inclusion in seasonal vaccines.
3.3. Overall response to influenza vaccination
The ability of licensed influenza vaccines to elicit an antibody response against vaccine anti-
gens was examined comparing HI antibody titers in blood samples collected from the 4461
volunteers before and 1 month after vaccination with commercially available seasonal triva-
lent inactivated influenza vaccines in 27 consecutive winters (from 1988–1989 to 2014–2015).
Figure 1. Recommended viruses for influenza vaccines by World Health Organization between 1988 and 2014.
Vaccine component 
(N = 4461) 
Seroprotection
rate (95% CI) 
Seroconversion 
rate (95% CI) 
GMT (95% CI)  Number of reached
CHMP criteria/3 
Prevacc. Postvacc. Prevacc. Postvacc.
[GMTR]
A/H3N2 35.1 A,B  65.7** A,B  30.0** A,B  20.9 A,B  54.6** A,B [2.6] 3/3 
(33.7–36.5) (64.3–67.1) (28.5–31.2)  (20.2–21.6) (52.5–56.8) 
A/H1N1 23.5  52.6**  25.1  14.2  35.3 ** [2.5]  1/3 
(22.2–24.7) (51.1–54.1) (23.8–26.0)  (13.7–14.6) (34.0–36.7) 
B 23.3  54.5**  25.6  14.5  35.7 ** [2.5]  1/3 
(22.1–24.5) (53.0–55.9) (24.3–27.1)  (14.1–14.9) (34.5–37.0) 
**: p-value < 0.01 comparing pre- and postvaccination values.
A: p-value <0.01 comparing A/H3N2 and A/H1N1 antigens.
B: p-value <0.01 comparing A/H3N2 and B antigens.
Table 2. Mean values of the HI antibody responses observed in the 27-years study of the total population to the three
influenza vaccine antigens and reachment CHMP criteria.
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The HI antibody response after one dose of influenza vaccine was evaluated for each antigen
(A/H1N1, A/H3N2, and B) and data obtained were processed in order to calculate, for each
population considered in the paper, pre- and postvaccination seroprotection rate, seroconver-
sion rate, pre- and postvaccination GMT, and GMTR together to their corresponding 95%
confidence intervals. For each antigen, the values of these parameters referred to the overall
population are reported in Table 2. One month after vaccination, statistically significant
increases were found in the percentage of seroprotected volunteers and in the values of their
corresponding GMT against all the three different vaccine antigens. The three CHMP require-
ments were satisfied 1 month after vaccination against the A/H3N2 vaccine component,
whereas only the requested value of GMTR was reached against the A/H1N1 and B antigens.
Table 3 reports the results obtained examining the reachment of the CHMP criteria for each
studied year against the three vaccine antigens. The seroprotection rate (HI titer ≥40) was
higher than the requested 60% in 20 years against A/H3N2 (74%), 16 years against A/H1N1
(59%), and 14 years against B antigen (52%) of the 27 years studied. Values of GMTR satisfying
the requested value ≥2 were found in 22 (81%), 25 (93%), and 21 (78%) years against A/H3N2,
A/H1N1, and B vaccine components, respectively. The lower positive results were found for
seroconversion requested to be ≥30%. This value was reached in 13 years against A/H3N2
(48%), 10 years against A/H1N1 (37%), and 8 years against B virus (30%). In some years none
of the three CHMP criteria was satisfied, i.e., in 3 years against A/H3N2 (11%), 2 years against
A/H1N1 (7%), and in 7 years against the B antigen (26%). Years with responses satisfying all
the three CHMP criteria ranged between 22% (B antigen) and 48% (A/H3N2 antigen). Because
the use of a vaccine featuring a novel antigen might affect the antibody response, considering
data reported about vaccine antigenic composition in Figure 1, we identified the presence or
absence of a novel vaccine component in each year studied, but we could not evidence any
obvious association between vaccine HI antibody response and the presence of a new vaccine
component.
Vaccine
component
N. of years (%) [95% CI]
Seroprotection
≥60%
Seroconversion
≥30%
GMTR ≥2 Reachment of
three CHMP
criteria
A/H3N2 20 (74%) [55–93] 13 (48%) [29–67] 22 (81%) [67–96] 13 (48%)
A/H1N1 16 (59%) [41–78] 10 (37%) [18–56] 25 (93%) [78–107] 8 (30%)
B 14 (52%) [33–71] 8 (30%) [11–48] 21 (78%) [64–92] 6 (22%)
Table 3. Reachment of the CHMP criteria in the total population in the 27 years examined.
The data reported in Table 2 evidenced differences in the values of the HI antibody titers
against the three different vaccine antigens. HI antibody values against A/H3N2 antigen were
in most instances significantly higher before and after vaccination as compared with those
found both against A/H1N1 and B vaccine components.
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Since the baseline serological status is considered to be important in evaluating immunoge-
nicity of influenza vaccines and is regarded as capable of affecting the serological outcomes,
in order to reduce the heterogeneity among the responses found against the three vaccine
antigens, we examined the GMT values of the overall population correcting the postvaccina-
tion titers for the prevaccination status according to Beyer (Figure 2) [18].
Figure 2. Postvaccination GMT values of: (a) the overall population corrected for the average prevaccination status ac-
cording to Beyer; and (b) subjects unprotected before vaccination. Comparison of antigens is also shown when differ-
ences are significant. The bars indicate the ranges of the 95% confidence limits.
For comparison purposes, also the postvaccination GMT values of the prevaccination unpro-
tected volunteers (HI < 40) are shown in Figure 2 as indicated by the corresponding labels. The
data reported confirmed that the responses against the A/H3N2 antigen were higher as
compared with those against A/H1N1 and B antigens.
3.4. Factors associated with vaccine response
Since different factors may have an impact on vaccine response, we controlled for a number
of variables for which we could obtain data. We did not consider the health status of the
study participants, previous vaccination histories, and living situation, since a high percent-
age of the subjects had chronic underlying disease, was previously vaccinated, and was liv-
ing in a nursing home.
3.4.1. Subanalysis according to different influenza vaccine dosages
In Italy, as in most European countries, seasonal trivalent influenza vaccines containing
10 μg HA for each antigen (30 μg) has been used until 1991. From 1992 onwards European
influenza vaccines contain 15 μg HA per strain (45 μg), according to the European Harmoni-
zation of Requirements for Influenza Vaccines [17]. As a consequence, in the first 4 years of
the 27-year period examined in our study, we used 30 μg and, after the winter 1991–1992, 45
μg vaccines.
Antibody Responses after Influenza Vaccination in Elderly People: Useful Information from a 27-Year Study...
http://dx.doi.org/10.5772/104559
223
Since previous observations suggested that increase in influenza vaccine dosage might be
associated with an increase in antibody titers, at least against some of the vaccine strains [19,
20], we compared HI immune response following vaccination with 30 or 45 μg vaccines. As
reported in Table 1, 860 (19%) and 3601 (81%) of the 4461 elderly subjects received respectively
a 30 or a 45 μg trivalent influenza vaccine. Table 4 reports the results obtained studying the
induced HI antibody response. Significant increases were observed against all the three vaccine
antigens comparing pre- and postvaccination data against all the three different vaccine
antigens examining the percentages of seroprotected people and GMT values both after 30 and
45 μg vaccine administration.
Vaccine component Vaccine
dose
(N)
Seroprotection
rate
Seroconversion 
rate (95% CI)
GMT (95% CI)
Prevacc. Postvacc. (95% CI) Prevacc. Postvacc.
[GMTR]
CHMP criteria
satisfied
A/H3N2 30 μg 14.1 A 39.3**A 16.9 A 13.2 A 26.3**A [2.0] 1/3
(860) (11.7–16.4) (36.0–42.6) (14.5–19.4) (12.4–14.0) (24.6–28.0)
45 μg 40.1 72.0** 32.9 23.3 65.1** [2.8] 3/3
(3601) (38.5–41.7) (70.5–73.5) (31.4–34.4) (22.4–24.3) (62.3–68.0)
A/H1N1 30 μg 10.2 35.7**A 20.8 A 9.5 A 22.5**A [2.4] 1/3
(860) (8.2–12.3) (32.5–38.9) (18.1–23.5) (8.9–10.0) (21.0–24.2)
45 μg 26.7 56.6** 26.1 15.6 39.4** [2.5] 1/3
(3601) (25.2–28.1) (55.0–58.3) (24.6–27.6) (15.0–16.2) (37.7–41.1)
B 30 μg 5.1 30.0**A 21.2 A 8.1 A 19.9**A [2.5] 1/3
(860) (3.6–6.6) (26.7–33.1) (18.4–24.1) (7.7–8.5) (18.5–21.3)
45 μg 27.6 60.3** 26.6 16.6 41.1** [2.5] 2/3
(3601) (26.2–29.1) (58.7–61.9) (25.2–28.0) (16.1–17.2) (39.6–42.7)
**: p-value <0.01 comparing pre- and postvaccination values.
A: p-value <0.01 comparing response between vaccine dosages (30 and 45 μg).
Table 4. HI antibody response in volunteers divided according to the vaccine dosage (30 or 45 μg).
At least one of the three CHMP requirements, i.e., the value of GMTR (≥2), was always reached
using vaccine containing 30 μg of antigen but following 45 μg vaccine administration all the
three parameters were satisfied against A/H3N2 antigen and two of them against the B antigen.
Postvaccination results observed after 45 μg vaccine administration were always significantly
higher as compared with those after 30 μg vaccine.
However, comparing values found in the two groups of people before vaccination, we observed
that the two groups were poorly comparable since there were differences in the prevaccination
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status. Volunteers vaccinated with 45 μg vaccine showed prevaccination HI titers in most
instances significantly higher as compared with the 30 μg volunteers. In order to have more
homogeneous and comparable data, we examined vaccine immunogenicity both correcting
the titers for prevaccination status of overall population [17], and considering only prevacci-
nation unprotected volunteers (HI titers < 40). As shown in Figure 3, GMT corrected for
prevaccination status confirmed that the increasing of the antigen dosage increments the
response to the vaccine antigens. Postvaccination values found considering only people
nonseroprotected before vaccination again evidenced a statistically significant higher response
induced by 45 μg vaccine as compared with 30 μg.
3.4.2. Subanalysis of immunogenicity within the elderly groups, i.e., younger elderly (≤75 years) and
very elderly (>75 years)
In a recent meta-analysis about the effect of age on the influenza vaccine–induced immune
response based on studies from the past 20 years, Goodwin at al. [12] concluded that aged
individual (>65 years) had a significantly reduced antibody response to vaccination. The
studied elderly were categorized into two age groups, above or below 75 years. Antibody
responses among the very elderly (≥75 years of age) were especially impaired with serocon-
version levels at 32%, 46%, and 29% to A/H1N1, A/H3N2, and influenza B, respectively,
compared with 42%, 51%, and 35% observed in people aged <75 to >65 years of age [12].
Figure 3. Postvaccination GMT values of populations divided according to the vaccine dosage (30 or 45 μg)), as indicat-
ed by legend labels. Postvaccination GMT values calculated on the overall population have been corrected for the aver-
age prevaccination status according to Beyer. For comparison purposes, post-GMT values of subjects unprotected
before vaccination are also shown. The bars indicate the ranges of the 95% confidence limits.
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In order to have additive information we considered the immune responses found in volun-
teers of our study aged ≤75 or >75 years. The exact age was available for only 2712 people
(61%) of the 4461 participants and 658 (24%) were aged ≤75 years and 2054 (76%) were
>75 years. The results obtained are reported in Table 5 and show that in both groups the
vaccine administration induced significant increases in HI titers evaluated as percentage of
seroprotected people (HI ≥ 40) and as GMT values. CHMP criteria were always satisfied for
GMTR parameter (≥2) against all the three vaccine antigens. All the three requested values
were reached in both groups against A/H3N2 antigen and only in >75 year group against A/
H1N1 antigen. Against the B antigen, the requested value for seroconversion (≥30%) was not
reached in both groups and the value for seroprotection (≥60%) was satisfied only in >75-
year group.
Vaccine component Group
(N)
Seroprotection
rate (95% CI)
Seroconversion
rate (95% CI)
GMT (95% CI)
Prevacc. Postvacc. Prevacc. Postvacc.
[GMTR]
CHMP criteria
satisfied
A/H3N2 ≤75 28.5 A 60.7 **A 31.8 16.5 A 46.9 **A [2.8] 3/3
(658) (24.1–30.9) (28.2–35.4) (56.9–64.4) (15.1–17.9) (42.5–51.7)
Age >75 40.1 71.4 ** 34.4 23.5 66.7 ** [2.8] 3/3
(2054) (37.9–42.2) (69.4–73.3) (32.4–36.4) (22.3–24.8) (62.7–70.9)
A/H1N1 ≤75 24.6 52.6 **A 24.5 A 14.2 a 35.6 **A [2.5] 1/3
(658) (21.3–27.9) (48.7–56.4) (21.2–27.8) (13.0–15.4) (32.3–39.3)
Age >75 26.9 60.3 ** 29.8 15.7 42.5 ** [2.7] 3/3
(2054) (25.0–28.8) (58.2–62.4) (27.8–31.8) (15.0–16.5) (40.1–44.9)
B ≤75 254.6A 54.3 **A 26.7 14.3 A 36.8 **A [2.6] 1/3
(658) (21.3–27.9) (50.4–58.0) (23.4–30.0) (13.2–15.5) (33.4–40.5)
Age >75 30.6 62.8 ** 26.4 18.0 42.6 ** [2.4] 2/3
(2054) (28.6–32.6) (60.7–64.9) (24.5–28.3) (17.2–18.8) (40.5–44.9)
**: p-value <0.01 comparing pre- and post-vaccination values.
A: p-value <0.01 comparing response between age groups.
a: p-value <0.05 comparing response between age groups.
Table 5. HI antibody response of populations divided according to the age (younger elderly, ≤75 years, and very
elderly, >75 years).
Comparing results obtained in the two groups, the responses observed in the oldest group
(>75) were in most instances higher than those observed in the younger elderly (≤75). However,
since the prevaccination status of these two groups were not fully comparable, we evaluated
the values of GMT corrected for prevaccination status and GMT in people unprotected (HI < 40)
before vaccination. Again the values were higher in the very elderly as compared with the
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younger against A/H1N1 for GMT corrected and against A/H1N1 and B for the GMT unpro-
tected people (Figure 4).
Figure 4. Postvaccination GMT values of populations divided according to the age class (younger elderly, ≤75 years,
and very elderly, >75 years), as indicated in legend labels. Postvaccination GMT values calculated on the overall popu-
lation have been corrected for the average prevaccination status according to Beyer. For comparison purposes, post-
GMT values of subjects unprotected before vaccination are also shown. The bars indicate the ranges of the 95%
confidence limits.
3.4.3. Subanalysis according to responses found in females and males
Previous data indicated that receipt of trivalent inactivated influenza vaccines results in
significantly higher HI antibody titers among females than males, both in adults and elderly
people [21].
In our study, sex data were available for about all the people studied (4457/4461) and the
volunteers were prevalently females (70%). We examined the vaccine immunogenicity in
females and males and the results are reported in Table 6. Postvaccination increases found
against all the three vaccine antigens were statistically significant in both groups. All the three
CHMP criteria were satisfied against A/H3N2 antigen in female subjects, whereas only the
GMTR requirement was satisfied in males against A/H3N2 and both in males and females
against A/H1N1 and B antigens. Comparison of postvaccination values evidenced statistically
higher values in the female compared with male group. However, since differences were found
also in the prevaccination values we compared the GMT corrected for the prevaccination status
and examined the GMT found considering only volunteers not seroprotected before vaccina-
Antibody Responses after Influenza Vaccination in Elderly People: Useful Information from a 27-Year Study...
http://dx.doi.org/10.5772/104559
227
tion. The female responses were again higher than those of male against all the three vaccine
antigens (Figure 5).
Vaccine
components
Group
(N)
Seroprotection
rate (95% CI)
Seroconversion
rate (95% CI)
GMT (95% CI) EMA
criteria
satisfied
Prevacc. Postvacc. Prevacc. Postvacc.
[GMTR]
A/H3N2 F 36.9 A 68.7 **A 32.7 A 21.7 A 60.0 **A [2.8] 3/3
(3142) (35.2–38.5) (67.1–70.3) (31.0–34.4) (20.8–22.6) (57.3–62.9)
M 30.9 58.6 ** 23.1 19.1 43.8 ** [2.3] 1/3
(1315) (28.4–33.4) (55.9–61.3) (20.8–25.4) (17.9–20.4) (40.9–46.9)
A/H1N1 F 24.1 55.3 **A 27.7 A 14.4 38.0 **A [2.6] 1/3
(3142) (22.6–25.6) (53.6–57.1) (26.2–29.2) (13.9–15.0) (36.3–39.8)
M 22.1 46.2 ** 18.7 13.6 29.8 ** [2.2] 1/3
(1315) (19.8–24.3) (43.5–48.9) (16.5–20.9) (12.8–14.4) (27.8–31.8)
B F 24.9 A 56.9 **A 26.7 A 15.2 A 38.2 **A [2.5] 1/3
(3142) (23.4–26.5) (55.2–58.6) (25.2–28.2) (14.6–15.7) (36.6–39.9)
M 19.3 48.6 ** 22.7 13.0 30.5 ** [2.4] 1/3
(1315) (17.2–21.5) (45.8–51.3) (20.5–25.4) (12.3–13.7) (28.7–32.4)
**: p-value <0.01 comparing pre- and post-vaccination values.
A: p-value <0.01 comparing response between M and F.
Table 6. HI antibody response of populations divided according to gender (male: M; female: F).
Figure 5. Postvaccination GMT values of populations divided according to gender (male: M and female: F) as indicated
in legend labels. Postvaccination GMT values calculated on the overall population have been corrected for the average
prevaccination status according to Beyer. For comparison purposes, post-GMT values of subjects unprotected before
vaccination are also shown. The bars indicate the ranges of the 95% confidence limits.
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3.4.4. Evaluation of vaccine immunogenicity in “strong responder”
Examining the antibody response after influenza vaccination, McElhaney et al. [22] consid-
ered as a vaccination efficiency-related parameter the HI antibody titer ratio between day 30
and day 0 and identified as weak/nonresponder people with a ratio 1– < 4 and as strong res-
ponders those with a ratio ≥4, i.e., people who seroconverted after vaccination. Using the
same parameter we decided to evaluate in the groups identified as strong responders the in-
duction of HI antibody response evaluated as GMT values against the three vaccine anti-
gens.
The data obtained comparing results found in people who seroconverted after vaccination are
reported in Table 7, and in most instances confirmed the results obtained examining the overall
population of subgroups vaccinated with vaccine containing different dosages of antigens or
subdivided in male and female. The responses induced by a 45 μg vaccine or in female were
in most instances statistically higher than those induced by a 30 μg vaccine or in male volun-
teers, respectively. Moreover, the immune responses evaluated in volunteers with an age ≤ or
>75 years were similar against A/H1N1 and B antigens and higher against the A/H3N2 antigen
in people aged >75 years as compared with response in those ≤75 years.
Group  A/H3N2  A/H1N1  B 
N
(total) 
GMT post
[GMTR]
(95% CI) 
Corrected
GMT
(95% CI) 
N
(total) 
GMT post
[GMTR]
(95% CI) 
Corrected
GMT
(95% CI) 
N
(total) 
GMT post
[GMTR]
(95% CI) 
Corrected
GMT
(95% CI) 
30 μg 146 84.0 A [7.6] 82.9 A 179 76.8 A [10.0] 86.81A 182 83.8 A [9.7] 94.1 A
(860) (77.2–91.5) (74.9–91.86) (860) (71.4–82.7) (80.3–93.85) (860) (77.9–90.1) (86.9–101.9)
45 μg 1185 164.7 [9.0] 133.6 940 127.4 [9.8] 126.1 959 110.2 [8.4] 118.9
(3601) (155.3–174.6) (125.–142.7) (3601) (120.0–135.3) (118.5–134.1) (3601) (104.3–116.4) (112.1–126.3)
≤75 209 127.7 A [9.2] 112.9 A 161 123.0 [10.0] 121.6 176 113.4 [9.1] 122.7
(658) (111.4–146.4) (99.3–128.3) (658) (106.1–142.6) (104.7–141.2) (658) (98.6–130.4) (105.3–143.1)
>75 707 183.3 [9.2] 146.2 612 127.6 [9.7] 128.35 543 112.8 [8.1] 117.3
(2054) (169.6–198.1) (133.5–159.9) (2054) (118.7–137.2) (119.3–138.2) (2054) (104.9–121.2) (108.6–126.7)
F 1027 162.1 A [8.9] 130.3 a 872 120.3 [9.9] 121.6 A 842 113 a [8.9] 120.9 A
(3142) (152.2–172.5) (121.7–139.6) (3142) (113.3–127.8) (114.4–129.3) (3142) (106.7–119.6) (113.8–128.4)
M 304 125.9 [8.4] 109.4 246 108.4 [9.3] 100.1 299 86.9 [7.8] 93.9
(1315) (113.4–139.7) (97.1–123.1) (1315) (96.9–121.3) (90.6–110.4) (1315) (79.9–94.4) (86.3–102.2)
**: p-value <0.01 comparing pre- and postvaccination values.
A: p-value <0.01; a: p-value <0.05 comparing response between different groups.
Table 7. HI antibody response of strong responder population divided according to the vaccine dosage (30 or 45 μg),
age class (younger elderly, μ75 years, and very elderly, >75 years), and gender (male: M; female: F).
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3.4.5. Subanalysis according to the different types of vaccine used
Finally, since different vaccine formulations (whole, subunit, split, MF59-adjuvanted, and in-
tradermally administered) were used in the 27 years studied, we compared the results ob-
tained after administration of the different types of vaccine. Chi-square and one-way
analysis of variance (ANOVA) were used for evaluating multiple comparisons among
groups vaccinated with the different vaccine types. Estimates and comparison intervals are
shown in Figure 6. Paired comparison p-values resulting from the multicomparison test are
reported in Tables 8 only when one-way ANOVA comparison identified potentially signifi-
cant differences.
Figure 6. Values of CHMP parameters against the three vaccine antigens following vaccination with whole (N = 863),
split (N = 996), subunit (N = 1094), MF-59 adjuvanted (N = 1343), and intradermally administered (N = 165) influenza
vaccines. The black-dashed bold line in each figure represents the CHMP threshold value for the corresponding pa-
rameter. The bars indicate the ranges of the 95% confidence limits.
All vaccines used induced HI antibody responses satisfying at least one (prevalently GMTR
value ≥2) of the three CHMP criteria. The antibody response induced by whole vaccine was in
most instances lower as compared with responses induced by the others vaccines (Table 8).
However, as reported in Table 1, many of the volunteers vaccinated with whole vaccine in the
first years of the study received a vaccine with a low dose of antigen (30 μg). The responses
induced by split and subunit vaccines against A/H3N2 and B antigens were similar; on the
contrary against A/H1N1 antigen, the response induced by split vaccine was significantly
lower as compared with subunit.
The two enhanced vaccines, MF59-adjuvanted and intradermal, induced similar and higher
responses compared with conventional vaccines against A/H3N2 antigen.
Against A/H1N1, the response induced by MF59-adjuvanted vaccine was in most instances
higher than conventional and intradermal vaccines.
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Against B antigen, intradermal vaccine induced higher HI response than that induced by
conventional and MF59-adjuvanted vaccines. In some cases the differences were statistically
significant.
p-Values (when <0.05)
Parameter Whole
/sub-u
Whole
/split
Whole
/MF59
Whole
/ID
Split
/sub-u
Split
/MF59
Split
/ID
Sub-u
/MF59
Sub-u
/ID
MF59
/ID
A/H3N2 antigen
Protection <0.01 <0.01 <0.01 <0.01 – <0.01 <0.01 <0.01 <0.01 –
Conversion – – <0.01 <0.01 – <0.01 <0.01 <0.01 <0.01 –
GMTR <0.01 – <0.01 <0.01 – <0.01 <0.05 <0.01 <0.01 –
A/H1N1 antigen
Protection <0.01 <0.01 <0.01 – <0.01 <0.01 – <0.05 <0.01 <0.01
Conversion – <0.01 <0.01 – <0.01 <0.01 – – – –
GMTR – <0.01 <0.01 – <0.01 <0.01 – – – –
B antigen
Protection <0.01 <0.01 <0.01 <0.01 <0.01 – – <0.01 <0.01 –
Conversion <0.01 <0.01 – <0.01 – – <0.05 – – <0.01
GMTR – – – – – – – <0.01 – <0.01
Whole: whole-virus vaccine; Sub-u: sub-unit vaccine; Split: split-virus vaccine; MF59: subunit MF59-adjuvanted
vaccine; ID: Intradermal subunit vaccine.
Table 8. Paired comparison of results obtained in volunteers divided in groups according to the type of vaccine used
for immunization. p-values resulting from the multicomparison test are reported only when one-way ANOVA
comparison identified potentially significant differences.
4. Discussion
This study describes the humoral antibody response of 4461 elderly frail institutionalized
volunteers prevalently vaccinated in the previous year after vaccination with influenza
inactivated trivalent vaccines commercially available for the different years studied during a
27-year period (from winter season 1988–1989 to 2014–2015).
The first data were obtained by examining the results found in the 27-year period studied as
crude mean responses and evidenced the ability of influenza vaccine administration to elicit
antibody response in elderly volunteers (Table 2). One month after vaccination, significant
increases were found against all the three vaccine antigens; however, vaccination induced
significantly higher HI antibody titers against A/H3N2 antigen as compared with A/H1N1 and
B strains. The higher responses against A/H3N2 strain were substantially confirmed consid-
ering the number of years in the 27-year period examined in which the CHMP criteria were
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fulfilled (Table 3) or comparing GMT values after correction for baseline titers or considering
responses in prevaccination unprotected people (Figure 2).
In accordance with our results, higher titers after vaccination against A/H3N2 strain were
previously found by Sasaki et al. [23] and Ohmit et al. [24], but it was not possible to discrim-
inate between the possibility that A/H3N2 antigen is more immunogenic than A/H1N1 and B
antigens or the possibility that the higher GMT and protection rate values might depend from
earlier contact with the A/H3N2 virus due to vaccination or natural infection. Since all the
volunteers were previously vaccinated, the possibility of the influence of a different circulation
of A/H3N2 strains is more acceptable. The A/H3N2 viruses have the highest rate of evolution
among the three influenza subtypes currently circulating, with antigenically distinct strains
emerging on average 2–5 years and capable of a better diffusion among the population [25].
Further considerations about the results obtained derive from post hoc analyses conducted to
determine whether vaccine dose, age, sex, and type of vaccine might influence the vaccine-
induced humoral immune response.
Although the issue of increase in the antibody titers following increase in influenza vaccine
dosage is not completely clarified [19, 20, 26], our data found using vaccines with 30 or 45 μg
of antigens for vaccine dose, suggested that the increase in influenza vaccine dosage is
generally associated with an increase in the induction of antibody titers. Significant antibody
titers increases were observed both administering vaccines with 30 or 45 μg of antigens for
vaccine dose against all the three vaccine antigens. However, postvaccination values following
vaccination with 45 μg vaccine were in most instances statistically higher as compared with
30 μg both considering mean values for the overall population (Table 4) or GMT corrected for
prevaccination status or calculated in prevaccination unprotected volunteers (Figure 3). In
accordance with these observations, recently (December 2009) in the United States, a high-dose
(60 μg HA per strain) trivalent inactivated influenza vaccine was licensed for people 65 years
of age or older. The high dose vaccine was found to improve in people aged ≥65 years both
antibody response and protection against laboratory-confirmed influenza illness [27, 28].
Considering vaccine immunogenicity in younger elderly (≤75 years) or in very elderly
(>75 years), vaccine administration induced statistically significant increases in both groups.
Comparing the two groups, the values were in many instances slightly higher in the very
elderly as compared with younger elderly, and in some instances the differences were
statistically significant. However, the differences persisted against A/H1N1 antigen both after
correction for prevaccination status or calculation in unprotected volunteers before vaccina-
tion, and against B antigen only considering responses in unprotected people (Figure 4). The
highest response of very elderly people as compared with younger elderly volunteers might
be due to the fact that they probably represent a more selected group of elderly people capable
of longer surviving and with a possible lower degree of age-associated alteration of the
immune system [29].
However, since the differences were particularly evident against the A/H1N1 strain and are in
accordance with previous data found in our laboratory showing in two different winter seasons
a higher ability to give HI antibody response against A/H1N1 strains of people born between
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1903 and 1919 as compared with volunteers born between 1920 and 1957, we cannot exclude
the possibility that the differences might be due to cross-reactivity generated from exposure
to the 1918 A/H1N1 virus or related A/H1N1 strains [30].
As far as sex could influence the immune response against influenza vaccines, our results
confirmed previous data indicating that receipt of trivalent inactivated influenza vaccines
results in significantly higher HI titers among females than males, both in adults and elderly
people [21]. Significant rises in antibody titers were found after vaccination both in males and
females, but the values observed in females were significantly higher as compared with males
(Table 6) and the differences persisted also considering only GMT of volunteers unprotected
before vaccination or GMT corrected for prevaccination status (Figure 5).
Sex hormones have been considered to be the most important mediators of sex differences and
males with high level of testosterone have been found to have low antibody responses after
influenza vaccination [31, 32].
However, since our data were obtained in elderly people, i.e., after the reproductive senes-
cence, they support the hypothesis that the sex hormones are not the only mediator of sex
differences in humoral response to influenza vaccination and there is the possibility that
genetic differences also might underlie sex-based differences in adaptive immune response to
viral vaccines [21, 33].
These results (vaccine dose, age, and sex) were, at least in part, confirmed also considering
responses evaluated in strong responder, i.e., in volunteers showing a positive response after
vaccination (Table 7).
Comparison of the different type of vaccines used in the 27-year period evidenced higher
immunogenicity of the new “enhanced vaccines” specially licensed for elderly individuals,
i.e., adjuvanted and intradermally administered vaccines, as compared with traditional whole,
subunit, and split vaccines (Table 7, Figure 6) supporting previously published data [34, 35].
Our study had several limitations. The most important are that our observations may apply
only to frail seniors living in care facilities and that the subanalysis groups were not fully
comparable. However, since institutionalized people represent a significant target group for
influenza vaccination, it is important to analyze their response to influenza vaccines. An
additional limitation is the lack of data demonstrating clinical efficacy against influenza
infection and illness. Although there is substantial evidence that HI antibody titers represent
a good correlate of protection from severe illness in young adults, the predictive value of these
measurements in older adults might be variable. Although the number of volunteers and of
winter seasons we examined was considerable and comparable to the data reported in a review,
differently from a review on influenza vaccine immunogenicity, the results obtained in each
year were considered cumulatively not taking into account of the different characteristics of
the vaccines used through the 27-year period. Indeed, the antigenic composition of influenza
vaccines differ, even considerably, from one year to another, since it is updated each year to
match the strains circulating in the community and inactivated influenza vaccines are available
in different formulations (whole, split, and subunit with or without adjuvants), which are
administered intramuscularly or intradermally. Moreover, a further aspect that should be
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carefully considered as compared with those of a review on HI antibody titers after influenza
vaccine administration is the HI assay itself. HI test is not standardized across laboratory and
was found to be highly variable and sensitive to factors such as reagents, erythrocyte source,
and virus passage history. The results reported in the present report were all obtained in the
same laboratory, although in different years and although, some changes were introduced in
the HI test used during the 27-year period as reported in Section 2.
In conclusion, our data evidenced that the use of influenza vaccination appears to be an
appropriate strategy to address the challenge of influenza infections of the elderly. However,
they underline the need of studies for new improved influenza vaccines, since, as previously
found, the vaccine-induced HI antibody responses against the three vaccine antigens were
different and resulted not satisfactory against A/H1N1 and B antigen, since the postvaccination
values of seroprotected volunteers were lower than the requested 60% (Table 3).
Moreover, they underline the necessity to expand researches and approaches to understand
immunosenescence and its relationship to vaccine-induced immunity in order to have more
valid vaccines. The vaccine-induced stimulation of HI antibody response following vaccination
was found not only to be higher against one vaccine component as compared with the other
two, but also to be influenced by different factors as vaccine dose, age, sex, and type of vaccine.
It is therefore important, as suggested by Lambert et al. [5], both to understand the mechanisms
that result in these differences and to use such information to devise more immunogenic
influenza vaccine candidates.
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